Medtronic's third-quarter fiscal 2026 results revealed adjusted earnings per share of $1.36, exceeding quarterly profit estimates driven by robust demand for heart devices. Despite the strong performance with revenues of $9 billion, which surpassed Street forecasts, the stock fell over 3% after the announcement, attributed to concerns over a projected $185 million headwind from tariffs. The company reaffirmed its full-year earnings outlook, projecting 5.5% organic revenue growth, while continuing its history of dividend increases for 48 consecutive years.
“MDT · has an expected move of · 4.8%”
“Medtronic · beats · quarterly profit estimates · on robust demand for heart devices”
“Medtronic · beat · quarterly profit estimates · on robust demand for heart devices”
“Medtronic · beats · quarterly profit estimates · on robust demand for heart devices”
“Medtronic · beat quarterly profit estimates · true · true”
“Medtronic · beats · quarterly profit estimates · due to robust demand for heart devices”
“Medtronic plc MDT · reported · third-quarter fiscal 2026 adjusted earnings per share (EPS) · $1.36”
“Medtronic plc MDT · fell · adjusted earnings per share (EPS) · 2.2%”
“Medtronic plc MDT · beat · Zacks Consensus Estimate · 2.07%”
“Medtronic · projects · organic revenue growth · 5.5%”
“Medtronic · secured · CE Mark for Sphere-360 · null”
“Medtronic · executed its M&A strategy with two key transactions · null · null”
